Zenobia Therapeutics

Zenobia Therapeutics is a private, preclinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) for solid tumors. The company is leveraging a novel payload technology platform designed to overcome common limitations of existing ADCs, such as tumor resistance and systemic toxicity. Operating in the high-growth oncology sector, Zenobia aims to advance its pipeline into clinical development, positioning itself as an attractive partner or acquisition target for larger pharmaceutical companies. Its success hinges on the preclinical validation of its platform and its ability to secure future funding to reach key clinical milestones.

Novel antibody-drug conjugate (ADC) platform focusing on the development of proprietary cytotoxic payloads designed to improve efficacy and safety in solid tumors, integrated with antibody engineering for optimal targeting.

The ADC field is highly competitive, dominated by large companies like AstraZeneca/Daiichi Sankyo, Gilead, and Pfizer, alongside numerous biotechs (e.g., ImmunoGen, Mersana, AbbVie). Zenobia competes by focusing on novel payload technology, but must differentiate against other next-generation approaches involving novel linkers, bispecific antibodies, and alternative payload classes.